DCPH - Deciphera Pharmaceuticals' Investigational Drug Shows Encouraging Response Rates In Rare Type Of Cancer | Benzinga
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) announced top-line results from the MOTION Phase 3 study of vimseltinib in patients with Tenosynovial Giant Cell Tumor (TGCT) not amenable to surgery.
The study met its primary endpoint in the intent-to-treat (ITT) population, demonstrating statistically significant and clinically meaningful improvement versus placebo in Objective Response Rate (ORR) at Week 25 of 40% for the vimseltinib arm and 0% for the placebo arm.
MOTION study met all key secondary endpoints with statistically significant and clinically meaningful improvements at Week 25 compared to placebo, including ORR ...